SCM
Stonepine Capital Management Portfolio holdings
AUM
$102M
This Quarter Return
+26.39%
1 Year Return
+40.04%
3 Year Return
+160.28%
5 Year Return
+195.28%
10 Year Return
–
AUM
$298M
AUM Growth
+$298M
(+25%)
Cap. Flow
+$25.1M
Cap. Flow
% of AUM
8.41%
Top 10 Holdings %
Top 10 Hldgs %
86.08%
Holding
25
New
6
Increased
9
Reduced
7
Closed
3
Top Buys
| 1 |
Galapagos
GLPG
|
$22.7M |
| 2 |
MaxCyte
MXCT
|
$12M |
| 3 |
ATYR
aTyr Pharma
ATYR
|
$10.1M |
| 4 |
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
|
$6.73M |
| 5 |
Xoma
XOMA
|
$5.35M |
Top Sells
| 1 |
APEN
Apollo Endosurgery, Inc.
APEN
|
$33.3M |
| 2 |
UroGen Pharma
URGN
|
$5.58M |
| 3 |
Xeris Biopharma Holdings
XERS
|
$4.16M |
| 4 |
Evolus
EOLS
|
$2.16M |
| 5 |
Mirum Pharmaceuticals
MIRM
|
$2.12M |
Sector Composition
| 1 | Healthcare | 99.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AMYT
1
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
| $91.5M | 30.7% | 6,278,085 -55,154 | -0.9% | -$804K |
|
|
2
Galapagos
GLPG
$2.07B
| $30.2M | 10.14% | 782,289 +587,453 | +302% | +$22.7M |
|
|
CTIC
3
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $27.4M | 9.21% | 6,535,674 +1,601,574 | +32% | +$6.73M |
|
4
ADMA Biologics
ADMA
$4.12B
| $25.4M | 8.51% | 7,661,690 +721,690 | +10% | +$2.39M |
|
5
QuidelOrtho
QDEL
$1.95B
| $24.9M | 8.34% | 279,081 -20,919 | -7% | -$1.86M |
|
|
6
Xeris Biopharma Holdings
XERS
$1.26B
| $14.1M | 4.72% | 8,640,205 -2,554,984 | -23% | -$4.16M |
|
|
7
MaxCyte
MXCT
$148M
| $13.4M | 4.49% | 2,707,090 +2,433,803 | +891% | +$12M |
|
|
THRD
8
DELISTED
Third Harmonic Bio
THRD
| $12.9M | 4.33% | 3,131,995 +1,116,694 | +55% | +$4.6M |
|
|
ATYR
9
aTyr Pharma
ATYR
$527M
| $10.1M | 3.4% | +4,825,722 | New | +$10.1M |
|
|
10
Xoma
XOMA
$392M
| $6.72M | 2.25% | 318,096 +253,637 | +393% | +$5.35M |
|
11
Castle Biosciences
CSTL
$696M
| $6.65M | 2.23% | 292,866 +114,626 | +64% | +$2.6M |
|
|
12
UroGen Pharma
URGN
$900M
| $6.48M | 2.17% | 701,535 -603,412 | -46% | -$5.58M |
|
13
Rezolute
RZLT
$619M
| $5.93M | 1.99% | 3,087,649 +66,145 | +2% | +$127K |
|
|
14
Evolus
EOLS
$494M
| $4.9M | 1.64% | 578,795 -255,637 | -31% | -$2.16M |
|
15
Dynavax Technologies
DVAX
$1.19B
| $4.09M | 1.37% | +416,519 | New | +$4.09M |
|
|
APEN
16
DELISTED
Apollo Endosurgery, Inc.
APEN
| $3.67M | 1.23% | 370,000 -3,356,584 | -90% | -$33.3M |
|
17
Travere Therapeutics
TVTX
$1.56B
| $2.97M | 1% | +132,005 | New | +$2.97M |
|
18
Exagen
XGN
$217M
| $2.52M | 0.85% | 1,037,074 +183,032 | +21% | +$445K |
|
19
Atea Pharmaceuticals
AVIR
$267M
| $2.29M | 0.77% | +684,508 | New | +$2.29M |
|
20
SCYNEXIS
SCYX
$34.9M
| $1.35M | 0.45% | +450,000 | New | +$1.35M |
|
|
CFMS
21
DELISTED
Conformis, Inc. Common Stock
CFMS
| $648K | 0.22% | 402,651 -345,543 | -46% | -$556K |
|
22
Cidara Therapeutics
CDTX
$1.66B
| $1.27K | ﹤0.01% | +1,000 | New | +$1.27K |
|
|
23
Mirum Pharmaceuticals
MIRM
$3.71B
| – | – | -108,769 | Closed | -$2.12M |
|
24
OmniAb
OABI
$230M
| – | – | -354,266 | Closed | -$1.28M |
|
|
OPTN
25
DELISTED
OptiNose
OPTN
| – | – | -508,284 | Closed | -$940K |
|